Assembly Biosciences, Inc. ASMB
Set alert
19.51 USD -0.62 -3.08%
At close · Nov 2
19.53 +0.02 +0.10%
After hours · Nov 2, 4:00 PM ET
19.25 Day range 20.77
19.25 52-week range 39.71
- YTD
- -42.63%
- 1 year
- -37.17%
- Open
- 20.37
- Prev close
- 20.13
- Mkt cap
- 397.24M
- Vol
- 262.71K
- Avg vol
- 292.54K
- EPS
- 1.04
- P/E
- 18.76
- Div yield
- 0.00%
More statistics
- Low
- 19.25
- High
- 20.77
- Forward P/E
- -2.12
- Beta
- 0.59
- Short ratio
- 0.41
- Inst. own
- 18.79%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 27, 2024
- 50-d avg
- 16.31
- 200-d avg
- 15.02
- 1y target
- 35.50
5Y chart
Events in this range
- Aug 9, 2023Earnings: -3.84; estimate -3.48; surprise -10.34%
- Nov 8, 2023Earnings: -3.24; estimate -2.76; surprise -17.39%
- Feb 12, 2024Split: 1 for 12
- Mar 27, 2024Earnings: —; estimate -2.88; surprise —%
- Apr 1, 2024Rating: HC Wainwright & Co. · — → Neutral
- May 8, 2024Earnings: -1.66; estimate -2.74; surprise 39.42%
- Jun 13, 2024Rating: HC Wainwright & Co. · — → Neutral
- Jun 20, 2024Rating: HC Wainwright & Co. · — → Neutral
- Aug 8, 2024Earnings: -1.98; estimate -2.96; surprise 33.11%
- Nov 7, 2024Earnings: -1.51; estimate -2.02; surprise 25.25%
Signals (89)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Mar 23, 2026 | 7 months ago |
| SMA: Bullish | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 29, 2025 | 10 months ago |
| SMA: Bearish | Dec 22, 2025 | 10 months ago |
| RSI: Overbought | Dec 8, 2025 | 10 months ago |
| RSI: Overbought | Oct 13, 2025 | 1 year ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Sep 29, 2025 | 1 year ago |
| SMA: Bullish | Sep 15, 2025 | 1 year ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| RSI: Overbought | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | May 26, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 28, 2025 | 1 year ago |
| RSI: Oversold | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
| SMA: Bullish | Dec 30, 2024 | 1 year ago |
| SMA: Bullish | Dec 30, 2024 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| SMA: Bearish | Dec 2, 2024 | 1 year ago |
| SMA: Bullish | Nov 25, 2024 | 1 year ago |
| SMA: Bullish | Nov 25, 2024 | 1 year ago |
| SMA: Bearish | Nov 18, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 4, 2024 | 1 year ago |
| SMA: Bearish | Oct 28, 2024 | 2 years ago |
| SMA: Bullish | Oct 7, 2024 | 2 years ago |
| SMA: Bearish | Sep 30, 2024 | 2 years ago |
| RSI: Overbought | Sep 16, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 2, 2024 | 2 years ago |
| SMA: Bullish | Aug 19, 2024 | 2 years ago |
| SMA: Bullish | Aug 12, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 8, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 1, 2024 | 2 years ago |
| SMA: Bearish | Jun 24, 2024 | 2 years ago |
| SMA: Bullish | May 6, 2024 | 2 years ago |
| SMA: Bearish | Apr 22, 2024 | 2 years ago |
| SMA: Bullish | Jan 22, 2024 | 2 years ago |
| SMA: Bullish | Dec 18, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 18, 2023 | 2 years ago |
| MACD: Sell Signal | Nov 6, 2023 | 2 years ago |
| MACD: Buy Signal | Oct 30, 2023 | 3 years ago |
| SMA: Bearish | Oct 23, 2023 | 3 years ago |
| SMA: Bullish | Oct 16, 2023 | 3 years ago |
| RSI: Oversold | Oct 9, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 18, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| SMA: Bullish | May 29, 2023 | 3 years ago |
| SMA: Bearish | May 22, 2023 | 3 years ago |
| MACD: Buy Signal | May 15, 2023 | 3 years ago |
| SMA: Bullish | May 8, 2023 | 3 years ago |
| RSI: Oversold | Mar 27, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 20, 2023 | 3 years ago |
| SMA: Bearish | Feb 20, 2023 | 3 years ago |
| SMA: Bearish | Feb 6, 2023 | 3 years ago |
| SMA: Bullish | Jan 23, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 9, 2023 | 3 years ago |
| SMA: Bullish | Jan 2, 2023 | 3 years ago |
| RSI: Oversold | Dec 5, 2022 | 3 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 12, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Jul 25, 2022 | 4 years ago |
| SMA: Bullish | May 30, 2022 | 4 years ago |
| SMA: Bullish | May 23, 2022 | 4 years ago |
| SMA: Bearish | Apr 25, 2022 | 4 years ago |
| SMA: Bullish | Mar 14, 2022 | 4 years ago |
Key statistics
- Market cap
- 93.56M
- Enterprise value
- 3.57M
- Trailing P/E
- 0.00
- Forward P/E
- -2.12
- PEG ratio
- 0.00
- Price / sales
- 4.36
- Price / book
- 1.96
- EPS (TTM)
- -6.89
- Beta
- 0.59
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -212.33%
- Revenue (TTM)
- 21.48M
- Revenue growth
- 0.00%
- Free cash flow
- 5.50M
- Total cash
- 109.22M
- Total debt
- 1.75M
- Return on equity
- -101.77%
- Shares outstanding
- 6.36M
- Short % of float
- 0.38%
- 50-day average
- 16.31
- 200-day average
- 15.02
Analyst view
Consensus: none
Price target (mean) 35.50 +82.0% upside
Now 19.51
- Target (low)
- 35.00
- Target (mean)
- 35.50
- Target (high)
- 36.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy0
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 27, 2024
Expected Mar 27, 2024. Consensus EPS estimate -1.75.
Financials — quick view
ASMB Revenue — quarterly 0
ASMB Net income — quarterly -3.86M
ASMB EPS — quarterly -0.20
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -2.02 | -1.51 | +0.51 | +25.25% |
| Aug 8, 2024 | Jun 1, 2024 | -2.96 | -1.98 | +0.98 | +33.11% |
| May 8, 2024 | Mar 1, 2024 | -2.74 | -1.66 | +1.08 | +39.42% |
| Mar 27, 2024 | Dec 1, 2023 | -2.88 | — | — | — |
| Nov 8, 2023 | Sep 1, 2023 | -2.76 | -3.24 | -0.48 | -17.39% |
| Aug 9, 2023 | Jun 1, 2023 | -3.48 | -3.84 | -0.36 | -10.34% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 20, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Jun 13, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| Apr 1, 2024 | HC Wainwright & Co. | reit | — | Neutral |
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- assemblybio.com
News
- Assembly Biosciences to Participate in Upcoming Investor Conferences
- Assembly Biosciences Doses First Two Patients In Its Phase 2 Clinical Trial Of ABI-6250 To Treat Chronic Hepatitis Delta Virus Infection
- Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
- Analyzing RYTHM (NASDAQ:RYM) and Assembly Biosciences (NASDAQ:ASMB)
- Assembly Biosciences To Present New Phase 1a Data From Its ABI-6250 Program At The Liver Meeting 2026
- Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
- Best Momentum Stocks to Buy for September 17th
- New Strong Buy Stocks for September 17th
- Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
- Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
Your note
Sign in to keep a note on ASMB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BJORKQUIST JEANETTE M | Officer | Sale | May 22, 2024 | 3,142 |
| DELANEY WILLIAM E IV | Officer | Stock Award(Grant) | Apr 28, 2024 | 16,109 |
| GILEAD SCIENCES INC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 16, 2024 | 1,268,970 |
| MCHUTCHISON JOHN G | Director | Sale | May 22, 2024 | 19,104 |
| OKAZAKI JASON A | Chief Executive Officer | Sale | Oct 2, 2024 | 14,904 |
| SCHORNSTEIN ALEXANDER | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 24, 2024 | 728,113 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 5.57% | 354,000 | 5.21M | Sep 29, 2024 |
| Vanguard Group Inc | 3.15% | 200,458 | 2.95M | Sep 29, 2024 |
| Blackrock Inc. | 1.21% | 77,108 | 1.14M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.03% | 65,624 | 965.99K | Sep 29, 2024 |
| Acuitas Investments LLC | 0.98% | 62,315 | 917.28K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.74% | 47,034 | 692.34K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.81% | 114,782 | 1.69M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.04% | 66,356 | 976.76K | Sep 29, 2024 |
| Federated Hermes MDT Mid Cap Growth Fund | 0.40% | 25,394 | 373.80K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.37% | 23,660 | 348.27K | Oct 30, 2024 |
| Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 0.28% | 17,723 | 260.88K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.22% | 13,750 | 202.40K | Sep 29, 2024 |